It is estimated that approximately 5–10% of breast, ovarian, and uterine cancers are due to an inherited genetic predisposition. In addition, a family history is found in about 10% of pancreatic cancers. Knowing one’s genetic predisposition makes it possible to develop targeted and personalized prevention and early diagnosis strategies.

These genetic tests are aimed at doctors and their patients to confirm a clinical suspicion or to search for any subjects at risk, in case of familiarity.

The tests detect the presence of pathogenetic variations in the genes investigated by NGS sequencing.

The tests have a sensitivity and specificity higher than 99%, each clinically significant variant is validated with a second method, in compliance with the most stringent guidelines of medical genetics.